Zobrazeno 1 - 10
of 25
pro vyhledávání: '"A. M. Chomakhidze"'
Autor:
E. I. Alekseeva, S. I. Valieva, T. M. Bzarova, R. V. Denisova, T. V. Sleptsova, O. L. Lomakina, A. M. Chomakhidze
Publikováno v:
Педиатрическая фармакология, Vol 13, Iss 4, Pp 390-394 (2016)
This article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in a two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal ant
Externí odkaz:
https://doaj.org/article/9e4fa09829bf4dbabbd00d6090e2ddd7
Autor:
T. M. Bzarova, Ye. I. Alekseeva, S. I. Valieva, R. V. Denisova, K. B. Isaeva, Ye. G. Chistyakova, A. M. Chomakhidze, T. V. Sleptsova, A. N. Fetisova, O. L. Lomakina, M. A. Soloshenko
Publikováno v:
Вопросы современной педиатрии, Vol 14, Iss 6, Pp 652-660 (2016)
Background: At present, it is urgent to find ways to overcome the inefficiency of and intolerance to the methotrexate therapy in patients with juvenile idiopathic arthritis (JIA). A promising method is the use of TNF-alpha inhibitors as monotherapy.O
Externí odkaz:
https://doaj.org/article/684f62cda9f84b2cabbdfa4088cfb0f0
Autor:
E. I. Alexeeva, T. M. Bzarova, S. I. Valieva, R. V. Denisova, K. B. Isaeva, E. G. Chistyakova, A. M. Chomakhidze, T. V. Sleptsova, N. I. Taibulatov, A. N. Fetisova, M. Sh. Shingarova
Publikováno v:
Вопросы современной педиатрии, Vol 14, Iss 4, Pp 464-476 (2015)
Background: Treatment of patients with juvenile idiopathic arthritis (JIA) is one of the most complex and urgent problems of rheumatology.Objective: Our aim was to evaluate the efficacy and safety of adalimumab therapy combined with immunosuppressant
Externí odkaz:
https://doaj.org/article/69be06a3af994846b8c5ae690962d944
Autor:
T. M. Bzarova, E. I. Alexeeva, S. I. Valieva, R. V. Denisova, K. B. Isaeva, E. G. Chistyakova, A. M. Chomakhidze, T. V. Sleptsova, A. N. Fetisova, N. I. Taibulatov
Publikováno v:
Вопросы современной педиатрии, Vol 14, Iss 4, Pp 489-496 (2015)
Background: An issue related to the terms of assignment of genetically engineered biological agents to patients with juvenile idiopathic arthritis (JIA) still remains debatable in pediatric rheumatology.Objective: Our aim was to evaluate the efficacy
Externí odkaz:
https://doaj.org/article/a820173d736749ee9b2272057a066d77
Publikováno v:
Вопросы современной педиатрии, Vol 14, Iss 2, Pp 219-223 (2015)
Modern successful treatment of rheumatic diseases is impossible without the use of intravenous immunoglobulin. The use of intravenous immunoglobulin is based on strict indications developed as a result of long-term multicenter controlled studies. The
Externí odkaz:
https://doaj.org/article/0b1cca2c191e473284102d60ddf204c6
Autor:
A. A. Baranov, E. I. Alexeeva, T. M. Bzarova, S. I. Valieva, K. B. Isaeva, E. G. Chistyakova, A. M. Chomakhidze, R. V. Denisova, T. V. Sleptsova, A. N. Fetisova, O. L. Lomakina
Publikováno v:
Вопросы современной педиатрии, Vol 14, Iss 2, Pp 224-235 (2015)
Treatment of juvenile idiopathic arthritis (JIA) is one of the most complex and urgent problems of rheumatology. Objective: We undertook a study to evaluate the effectiveness and safety of long-term therapy with etanercept in patients with JIA withou
Externí odkaz:
https://doaj.org/article/b24614b13bea42e49b3806b11d2c0dc4
Autor:
E. I. Alexeeva, R. V. Denisova, T. V. Sleptsova, T. M. Bzarova, K. B. Isaeva, E. V. Mitenko, E. G. Chistyakova, A. M. Chomakhidze, N. I. Taybulatov, A. N. Fetisova, O. L. Lomakina, S. I. Valieva
Publikováno v:
Педиатрическая фармакология, Vol 11, Iss 2, Pp 88-94 (2014)
The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceu
Externí odkaz:
https://doaj.org/article/74f2cdba75ec4660a374045f500a0598
Autor:
E. I. Alexeeva, T. V. Sleptsova, T. M. Bzarova, S. I. Valieva, R. V. Denisova, K. B. Isaeva, E. V. Mitenko, E. G. Chistyakova, A. M. Chomakhidze, A. N. Fetisova, O. L. Lomakina, N. I. Taybulatov
Publikováno v:
Педиатрическая фармакология, Vol 11, Iss 2, Pp 48-54 (2014)
This article presents a case of severe course of polyarticular juvenile idiopathic arthritis. Active articular syndrome, high laboratory parameters of disease activity, severe incompetence were observed in a child by the therapy initiation. Successfu
Externí odkaz:
https://doaj.org/article/e60f8268ef044e719c7bd5f20e00bc5d
Autor:
A. A. Baranov, E. I. Alexeeva, S. I. Valieva, T. M. Bzarova, E. V. Mitenko, R. V. Denisova, A. N. Fetisova, T. V. Sleptsova, K. B. Isaeva, E. G. Chistyakova, N. I. Taibulatov, A. M. Chomakhidze
Publikováno v:
Вопросы современной педиатрии, Vol 13, Iss 1, Pp 33-50 (2014)
Aim: to assess efficacy and safety of «changeover» to the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) with resistance or intolerability to the first GEBA. Patients and methods: the resu
Externí odkaz:
https://doaj.org/article/d724ef3e3e05462d9c6658f4c7114e52
Autor:
R. V. Denisova, E. I. Alexeeva, K. B. Isaeva, T. V. Sleptsova, T. M. Bzarova, S. I. Valieva, E. V. Mitenko, E. G. Chistyakova, A. M. Chomakhidze, A. N. Fetisova, O. L. Lomakina
Publikováno v:
Вопросы современной педиатрии, Vol 12, Iss 6, Pp 123-129 (2013)
A history case of systemic juvenile idiopathic arthritis with early onset and severe clinical case, resistant to treatment with standard immunosuppressive agents is represented in the article. This case demonstrates high clinical efficacy of adalimum
Externí odkaz:
https://doaj.org/article/b22eb9e7007a4b1d8e0c20f5a0bca06b